Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan van Lunzen

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Virology|October 17, 2015
Patient-adapted, specific activation of HIV-1 by customized TAL effectors (TALEs), a proof of principle studyRene Geissler, Ilona Hauber, Nancy Funk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2006
Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cellsZoltán Bánki, Doris Wilflingseder, Christoph G Ammann, et al.
Lancet (London, England)|April 2, 2013
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirsChristine Katlama, Steven G Deeks, Brigitte Autran, et al.
AIDS (London, England)|February 26, 2015
Low SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1Nicolas Ruffin, Vedran Brezar, Diana Ayinde, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 9, 2016
Brief Report: Increased Frequency of CD39+ CD56bright Natural Killer Cells in HIV-1 Infection Correlates With Immune Activation and Disease ProgressionPatrick Dierks, Raluca Wroblewski, Johanna M Eberhard, et al.
Plos One|January 31, 2019
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruptionJürgen K Rockstroh, David Asmuth, Giuseppe Pantaleo, et al.
Vaccine|October 23, 2013
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled studyThomas Harrer, Andreas Plettenberg, Keikawus Arastéh, et al.
Leukemia & Lymphoma|October 27, 2006
AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effectiveChristian Hoffmann, Eva Wolf, Christoph Wyen, et al.
Lancet (London, England)|April 5, 2014
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b studyBonaventura Clotet, Judith Feinberg, Jan van Lunzen, et al.
Blood|July 23, 2011
Improved outcome with rituximab in patients with HIV-associated multicentric Castleman diseaseChristian Hoffmann, Holger Schmid, Markus Müller, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Virology|October 17, 2015
Patient-adapted, specific activation of HIV-1 by customized TAL effectors (TALEs), a proof of principle studyRene Geissler, Ilona Hauber, Nancy Funk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2006
Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cellsZoltán Bánki, Doris Wilflingseder, Christoph G Ammann, et al.
Lancet (London, England)|April 2, 2013
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirsChristine Katlama, Steven G Deeks, Brigitte Autran, et al.
AIDS (London, England)|February 26, 2015
Low SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1Nicolas Ruffin, Vedran Brezar, Diana Ayinde, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 9, 2016
Brief Report: Increased Frequency of CD39+ CD56bright Natural Killer Cells in HIV-1 Infection Correlates With Immune Activation and Disease ProgressionPatrick Dierks, Raluca Wroblewski, Johanna M Eberhard, et al.
Plos One|January 31, 2019
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruptionJürgen K Rockstroh, David Asmuth, Giuseppe Pantaleo, et al.
Vaccine|October 23, 2013
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled studyThomas Harrer, Andreas Plettenberg, Keikawus Arastéh, et al.
Leukemia & Lymphoma|October 27, 2006
AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effectiveChristian Hoffmann, Eva Wolf, Christoph Wyen, et al.
Lancet (London, England)|April 5, 2014
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b studyBonaventura Clotet, Judith Feinberg, Jan van Lunzen, et al.
Blood|July 23, 2011
Improved outcome with rituximab in patients with HIV-associated multicentric Castleman diseaseChristian Hoffmann, Holger Schmid, Markus Müller, et al.
Pageof 12